Iovance Biotherapeutics (IOVA) PT Raised to $22.00

Iovance Biotherapeutics (NASDAQ:IOVA) had its price objective upped by stock analysts at HC Wainwright from $16.00 to $22.00 in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 60.58% from the company’s previous close.

IOVA has been the subject of a number of other research reports. Oppenheimer reiterated a “buy” rating and set a $13.00 price objective on shares of Iovance Biotherapeutics in a research report on Monday, November 13th. Zacks Investment Research cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 20th. B. Riley reiterated a “buy” rating and set a $18.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, December 13th. Jefferies Group reiterated a “buy” rating on shares of Iovance Biotherapeutics in a research report on Sunday, October 29th. Finally, BidaskClub upgraded Iovance Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 20th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Iovance Biotherapeutics has an average rating of “Buy” and a consensus target price of $15.39.

Iovance Biotherapeutics (IOVA) traded down $0.95 during trading on Thursday, reaching $13.70. The company had a trading volume of 2,362,774 shares, compared to its average volume of 903,492. The stock has a market capitalization of $930.54, a PE ratio of -10.46 and a beta of 4.89. Iovance Biotherapeutics has a 12 month low of $4.45 and a 12 month high of $14.85.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). equities analysts predict that Iovance Biotherapeutics will post -1.36 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. increased its position in Iovance Biotherapeutics by 36.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 302,175 shares of the biotechnology company’s stock worth $2,418,000 after buying an additional 80,160 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Iovance Biotherapeutics in the third quarter worth about $2,325,000. Perceptive Advisors LLC increased its position in Iovance Biotherapeutics by 8.3% in the third quarter. Perceptive Advisors LLC now owns 4,726,114 shares of the biotechnology company’s stock worth $36,627,000 after buying an additional 363,000 shares in the last quarter. Orbimed Advisors LLC increased its position in Iovance Biotherapeutics by 89.9% in the third quarter. Orbimed Advisors LLC now owns 6,425,626 shares of the biotechnology company’s stock worth $49,799,000 after buying an additional 3,042,726 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in Iovance Biotherapeutics in the third quarter worth about $164,000. Institutional investors and hedge funds own 75.92% of the company’s stock.

WARNING: “Iovance Biotherapeutics (IOVA) PT Raised to $22.00” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/27/iovance-biotherapeutics-iova-pt-raised-to-22-00.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply